portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 Lee's Pharmaceutical Gains China Rights To Labor-Inducing Drug
 
CreateTime:2014-02-21 Editor:liaoyan
Text Size:       
 

Lee’s Pharma has in-licensed China Rights to tafoxiparin, a clinical-stage product from Dilafor AB of Sweden. Tafoxiparin is a heparin derivative that has completed a Phase II trial as a treatment to induce labor. Lee’s will be responsible for conducting Phase II and III trials of the drug in China. Specific financial terms of the deal were not disclosed.


Related Reports
China Pharmaceutical Glass Packaging Industry Report, 2014-2017
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1